Welcome to our dedicated page for Avadel Pharmaceu SEC filings (Ticker: AVDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avadel Pharmaceuticals plc (Nasdaq: AVDL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. Avadel is an Ireland-incorporated biopharmaceutical company focused on sleep-related disorders, and its filings provide detailed information on its commercial product LUMRYZ, clinical programs, licensing arrangements and corporate transactions.
Investors can review Avadel’s Form 10-K annual reports and Form 10-Q quarterly reports for narrative and quantitative discussions of LUMRYZ net product revenue, patient uptake, research and development spending, and risk factors related to narcolepsy, idiopathic hypersomnia and broader business operations. Current reports on Form 8-K highlight material events such as the Transaction Agreement and subsequent amendment with Alkermes plc, the proposed court-sanctioned scheme of arrangement under Irish law, settlement and license agreements with Jazz Pharmaceuticals, and the exclusive global license for valiloxybate from XWPharma.
These filings also document key clinical and regulatory milestones, including the FDA approvals that made LUMRYZ the first and only once-at-bedtime oxybate for extended-release oral suspension for cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy, Orphan Drug Exclusivity grants, and the design and status of Phase 3 studies such as REST-ON and REVITALYZ. Transaction-related disclosures describe the structure, consideration and conditions of the proposed acquisition by Alkermes and the evaluation of alternative proposals under the Irish Takeover Rules.
On Stock Titan, each new AVDL filing from EDGAR is surfaced in real time and paired with AI-powered summaries that explain the main points in clear language. Users can quickly see which filings involve LUMRYZ clinical data, royalty and license agreements, or the Alkermes acquisition terms, and can drill down into the full text for deeper analysis. Insider ownership and compensation details, when disclosed in proxy materials and related documents, are also accessible through the SEC filings stream, helping investors build a comprehensive view of governance and incentives at Avadel.
Avadel Pharmaceuticals plc reports that a U.S. District Court has ordered its subsidiary Avadel CNS Pharmaceuticals to pay Jazz Pharmaceuticals a future ongoing royalty of 3.85% on sales of its sleep medicine LUMRYZ. This royalty will apply through the expiration of Jazz’s U.S. Patent No. 11,147,782 on February 18, 2036.
Avadel disagrees with the underlying jury decision on the patent’s validity and plans to keep contesting both that decision and the related royalty obligation. Despite this, the company states that it has been accruing this royalty and will continue to recognize the related liability on its balance sheet, indicating that the financial impact of the royalty is being reflected in its accounting.
Geoffrey M. Glass, a director of Avadel Pharmaceuticals plc (AVDL), reported a non-cash transfer on Form 4 dated 09/15/2025. He transferred 11,000 stock options with an exercise price of $10.83 and an original grant exercisable from 07/29/2035 to the Geoffrey M. Glass Revocable Trust dated August 26, 2020, of which he is trustee. The options vest in full on the earlier of July 29, 2026 or the next annual shareholders' meeting following grant, subject to continued service. The filing was signed by an attorney-in-fact on Glass’s behalf.
Avadel Pharmaceuticals entered an exclusive global license agreement with XWPharma for valiloxybate, a GABAB receptor agonist for sleep disorders including narcolepsy and idiopathic hypersomnia. The license covers worldwide rights excluding mainland China, Hong Kong and Macau.
Avadel has paid XWPharma an upfront $15 million and will pay an additional $5 million in the fourth quarter of 2025. XWPharma may receive up to $30 million in development milestones, up to $155 million in tiered sales milestones tied to annual net sales up to $750 million, and additional performance-based sales milestone payments equal to 10% of each sales milestone for annual net sales exceeding $750 million and up to $3.5 billion. The agreement also includes tiered royalties from high-single digit to mid-teens on annual net sales and a $10 million milestone after the first U.S. commercial sale for each indication beyond narcolepsy and idiopathic hypersomnia following FDA approval.
The agreement runs until expiration of the applicable royalty terms and includes customary provisions on termination, representations, covenants and indemnification, with Avadel able to terminate for convenience subject to a notice period.
Janus Henderson Group plc reports beneficial ownership stakes in Avadel Pharmaceuticals plc common stock on a Schedule 13G/A filing. The filing names Janus Henderson as the reporting person and lists aggregate holdings of approximately 11.13 million shares (shown as 11,132,131 in one section and 11,080,442 in Item 4), representing about 11.5%–11.4% of the class. The filing identifies indirect subsidiaries JHIUS, JHIUKL and JHIAIFML as involved in investment-advisory activities and states the position is held in the ordinary course of business and not to influence control. The statement is signed by Janus Henderson compliance on 08/14/2025 and references the issuer address in Dublin.
Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi filed a Schedule 13G/A reporting that Two Seas Global (Master) Fund LP holds 6,155,074 ordinary shares of Avadel Pharmaceuticals plc (CUSIP G29687103), representing 6.4% of the class as of June 30, 2025. The filing states that Two Seas Capital LP, as investment adviser to the Global Fund, and Two Seas Capital GP LLC, as its general partner, each may be deemed to have sole voting and dispositive power over these shares, and that Sina Toussi may be deemed to have those powers through his roles with the adviser and GP. The principal business office for the reporting persons is listed as 32 Elm Place, 3rd Floor, Rye, New York 10580. The filing references 96,777,000 shares outstanding used to calculate the 6.4% stake and is signed by Sina Toussi on 08/13/2025. The report covers the event date 06/30/2025.